LivaNova (LIVN) Net Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -771.11% |
| Dec 31, 2025 | -120.42% |
| Sep 30, 2025 | 133.95% |
| Jun 30, 2025 | -1,838.59% |
| Mar 31, 2025 | -86.19% |
| Dec 31, 2024 | 121.14% |
| Sep 30, 2024 | 54.32% |
| Jun 30, 2024 | -53.59% |
| Mar 31, 2024 | 10.77% |
| Dec 31, 2023 | 867.20% |
| Sep 30, 2023 | -66.69% |
| Jun 30, 2023 | 182.86% |
| Mar 31, 2023 | -33.73% |
| Dec 31, 2022 | -94.09% |
| Sep 30, 2022 | 414.99% |
| Jun 30, 2022 | -113.91% |
| Mar 31, 2022 | 785.98% |
| Dec 31, 2021 | 118.14% |
| Sep 30, 2021 | -291.41% |
| Jun 30, 2021 | 5,807.65% |
| Mar 31, 2021 | -94.45% |
| Dec 31, 2020 | 502.96% |
| Sep 30, 2020 | -105.46% |
| Jun 30, 2020 | 60.70% |
| Mar 31, 2020 | 537.86% |
| Dec 31, 2019 | -147.03% |
| Sep 30, 2019 | 575.25% |
| Jun 30, 2019 | -271.85% |
| Mar 31, 2019 | 112.37% |
| Dec 31, 2018 | -196.03% |
| Sep 30, 2018 | 357.57% |
| Jun 30, 2018 | 58.54% |
| Mar 31, 2018 | -210.76% |
| Dec 31, 2017 | 30.37% |
| Sep 30, 2017 | 197.37% |
| Jun 30, 2017 | -197.96% |
| Mar 31, 2017 | 200.24% |
| Dec 31, 2016 | -5,952.16% |
| Oct 18, 2015 | 59.12% |
| Jul 24, 2015 | 475.21% |